Nath Bio-Genes Intrinsic Value
Nath Bio-Genes (NATHBIOGEN) median intrinsic value is ₹121.44 from 8 valuation models (range ₹65–₹339), vs current price ₹196.01 — -38.0% downside (Trading Above Calculated Value), margin of safety -61.4%. For current market price and key ratios, visit Nath Bio-Genes share price today.
NATHBIOGEN Valuation Methods Summary — DCF, Graham Number & P/E
Nath Bio-Genes intrinsic value across 8 models vs current price ₹196.01 — upside/downside and value range per method. Also explore Nath Bio-Genes share price performance to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹121.44 | ₹97.15 - ₹145.73 | -38.0% | EPS: ₹10.12, Sector P/E: 12x |
| Book Value Method | asset | ₹338.95 | ₹305.06 - ₹372.85 | +72.9% | Book Value/Share: ₹338.95, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹80.84 | ₹72.76 - ₹88.92 | -58.8% | Revenue/Share: ₹101.05, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹126.32 | ₹113.69 - ₹138.95 | -35.6% | EBITDA: ₹40.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹78.40 | ₹62.72 - ₹94.08 | -60.0% | CF Growth: 1.9%, Discount: 15% |
| PEG Ratio Method | growth | ₹64.77 | ₹58.29 - ₹71.25 | -67.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹83.39 | ₹75.05 - ₹91.73 | -57.5% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹277.81 | ₹250.03 - ₹305.59 | +41.7% | EPS: ₹10.12, BVPS: ₹338.95 |
NATHBIOGEN Intrinsic Value vs Market Price — All Valuation Models
Nath Bio-Genes fair value range ₹65–₹339 vs current market price ₹196.01 across 8 valuation models. Read Nath Bio-Genes dividend payments for the complete payout history and dividend yield track record.
NATHBIOGEN Intrinsic Value Analysis — Undervalued or Overvalued?
Nath Bio-Genes median intrinsic value ₹121.44, current price ₹196.01 — Trading Above Calculated Value by 38.0%, margin of safety -61.4%.
What is the intrinsic value of NATHBIOGEN?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Nath Bio-Genes (NATHBIOGEN) is ₹121.44 (median value). With the current market price of ₹196.01, this represents a -38.0% variance from our estimated fair value.
The valuation range spans from ₹64.77 to ₹338.95, indicating ₹64.77 - ₹338.95.
Is NATHBIOGEN undervalued or overvalued?
Based on our multi-method analysis, Nath Bio-Genes (NATHBIOGEN) appears to be trading above calculated value by approximately 38.0%.
NATHBIOGEN Financial Health — Key Ratios vs Industry Benchmarks
Nath Bio-Genes financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 40.59 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 3.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 14.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.19x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
NATHBIOGEN Cash Flow Quality — Operating & Free Cash Flow
Nath Bio-Genes operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹18 Cr | ₹16 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹75 Cr | ₹62 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹38 Cr | ₹37 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹17 Cr | ₹7 Cr | Positive Free Cash Flow | 7/10 |